ICYMI: CAPA Applauds Passage of Cornyn/Blumenthal Bill Out of the Senate Judiciary Committee Marking Another Step Closer Towards Ending Big Pharma’s Patent Abuse
Congress Must Stop Major Drug Companies from Abusing the U.S. Patent System to Delay or Prevent Patients from Accessing More Affordable Generic Alternative Medications and Treatments.
WASHINGTON D.C. – In case you missed it, the Senate Judiciary Committee voted unanimously to pass a package of four bills relating to drug pricing, including S. 1435, the Affordable Prescriptions for Patients Act of 2021, sponsored by Senator John Cornyn (R-TX) and Senator Richard Blumenthal (D-CT). This bill aims to reduce anticompetitive product-hopping and curtail the creation of large patent thickets by Big Pharma which prevents or delays competition in the marketplace from generic drug alternatives.
“CAPA applauds Senators on both sides of the aisle for passing this legislation out of Committee as a much-needed first step towards preventing major drug companies from gaming the U.S. patent system in pursuit of higher profits. The Affordable Prescriptions for Patients Act of 2021 is a necessary step towards tackling Big Pharma’s blatant patent abuses that protect their monopolies at the expense of patients and the entire healthcare system. There is certainly more work to be done, including strengthening tools such as the inter partes review process so that the U.S. Patent and Trademark Office can more effectively invalidate low-quality patents that should have never been granted in the first place. Moving forward, our Coalition looks forward to continuing our work with all stakeholders to rein in Big Pharma’s rampant patent abuse,” stated CAPA Executive Director Matthew Lane.
To watch a video of the recent markup, click here.